四環醫藥(00460.HK)附屬擬收購高品質美學和生物醫學產品製造商Genesis全部股權
格隆匯12月30日丨四環醫藥(00460.HK)發佈公吿，公司附屬公司耀忠國際與美國Genesis Biosystems, Inc.(“Genesis”)的原股東於2021年12月28日簽署收購協議，雙方協議由耀忠國際收購Genesis的全部股權。
美國Genesis成立於2001年，是一家高品質美學和生物醫學產品製造商，主要從事美容設備的開發、製造和分銷，專注於微通道系統和脂肪採集產品，用於美容護膚治療以及整形手術。
Genesis的微通道系統產品包括Derma Genesis®、Dermacel® 和DermaFrac®等系列產品，該系列產品通過纖細微小的微針進入肌膚，藉由真空吸力在皮膚上均勻的創造微細孔道，此細微傷口不會讓皮膚有出血反應，無副作用、無恢復期。 Genesis的脂肪採集系統LipiVage® 是一種創新產品，具有獨立性、即用型的兩步式脂肪收集、清洗和轉移系統，操作簡單，效果温和，具有無菌包裝設備的安全性和便利性，是常規負壓吸脂技術的改良版。於2021年6月，集團的美國附屬公司Meiyen Laboratory Inc已就該產品與Genesis達成戰略合作，取得該產品在大中華區及韓國的獨家代理權。
此次收購事項將進一步擴充集團的醫美產品管線，夯實集團在非手術和手術類醫美領域的全面佈局，及進一步加快推動集團醫美業務從產品代理向一體化平台型企業發展的進程。
集團旗下醫美平台渼顏空間立足於高增長、低滲透率的中國醫美市場，致力於以製藥企業的嚴謹創新打造醫美全產品矩陣龍頭企業。自2014年與韓國Hugel公司簽訂肉毒毒素及玻尿酸產品的獨家代理協議，以此為標誌開展了在醫美領域的佈局，經過多年的發展，集團不僅形成了數十款“自研+BD”的產品矩陣，還落成了美國研發中心渼顏實驗室及三個高效率、低成本的生產基地。作為聚焦中國的“一站式”新型醫美平台，渼顏空間預計將通過全球化佈局及本地化生產、全面專業的產品矩陣、強大的研發及註冊能力，以及多元化營銷能力和全面的渠道覆蓋來實現打造國際化醫美領先企業的戰略目標。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
